Cytosorbents Corp has taken a significant step to strengthen its financial position by entering into two securities purchase agreements. This move, which aims to raise approximately $4 million, is crucial for the company as it seeks to reduce its outstanding debt and enhance its working capital.
The offering involves the sale of 556,681 shares of common stock at a price of $4.94 per share, along with additional shares offered to directors and executive officers at a slightly higher price. The company is also providing pre-funded warrants to certain investors, allowing them to purchase shares at a nominal exercise price.
Founded in Delaware, Cytosorbents Corp operates in the surgical and medical instruments and apparatus sector. The company trades under the ticker CTSO on the Nasdaq exchange. This latest filing follows a series of recent filings, including a 10-Q and multiple 8-K forms, indicating ongoing financial activities and adjustments.
According to the filing dated November 20, 2026, the offering is expected to close on or about November 20, 2026, pending customary closing conditions. The gross proceeds from the offering are estimated at around $4 million, with net proceeds expected to be approximately $3.5 million after expenses.
The funds raised will primarily be used to repay $3 million of principal under an existing loan agreement with Avenue Capital, along with associated fees. The remaining funds will be allocated for general corporate purposes and working capital needs.
This securities offering is being facilitated by H.C. Wainwright & Co., LLC, acting as the exclusive placement agent, with WBB Securities, LLC serving as a financial advisor. The financial advisory fee for WBB is set at $30,000.
In conjunction with the offering, Cytosorbents also entered into a third amendment to its loan agreement with Avenue Capital. This amendment restructures some of the company's outstanding debt, allowing for a cash repayment of $3.3 million while also enabling the issuance of additional shares to satisfy part of the debt.
The company plans to issue approximately 202,429 shares to Avenue as part of this restructuring, valued at the same price as the common stock sold in the offering. This move is expected to significantly reduce the company's overall debt burden.
The Avenue Amendment also extends the interest-only period for the loan until March 31, 2028, with a possible extension contingent on achieving FDA marketing approval. The maturity date for the loan has been pushed to July 1, 2028, providing Cytosorbents additional time to manage its financial obligations.
Overall, this strategic financing initiative reflects Cytosorbents' commitment to improving its financial health while navigating the competitive landscape of the surgical and medical instruments industry. The company is positioning itself to better support its operations and growth plans in the future.
As the offering progresses, stakeholders will be watching closely to see how these financial maneuvers impact Cytosorbents' market position and operational capabilities. The filing does not specify any further actions or upcoming votes related to this offering.
Read Next
Interactive Strength amends Exchange Agreements with holders
Proto Labs Appoints Frank Klein to Board of Directors
NB Bancorp announces stock repurchase plan for 2.19M shares
WeRide Inc. Reports 88% Revenue Growth in Q3 2026 Results
Federal Home Loan Bank of Atlanta Issues New Financial Obligations
InterContinental Hotels Group Announces Make-Whole Redemption








